stockrowIndivior Pharmaceuticals Inc.
SUPN Healthcare Drug Manufacturers Specialty & Generic
Indivior Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 4.29% from fiscal 2024.
- Revenue
- +13.4%
- EPS
- +241.5%
- Free cash flow
- +240.7%
- Total debt
- +51.6%
Quarter to September 2026, against a year earlier
Follow SUPN
Alert me
Indivior Pharmaceuticals Inc. (SUPN) Free cash flow margin
Indivior Pharmaceuticals Inc.'s free cash flow margin over the twelve months to 30 September 2026 was 2.26%, up 9.8 percentage points from fiscal 2025 (−7.59%). Over the past ten years it has ranged from −32.3% (fiscal 2023) to 42.9% (fiscal 2021); the current reading is higher than 27% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 0.00% and above the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Embed this chart
Annual newest first
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2025 | −7.59% | (8.01) |
| FY2024 | 0.42% | 32.72 |
| FY2023 | −32.3% | (31.30) |
| FY2022 | −1.00% | (43.86) |
| FY2021 | 42.9% | 73.31 |
| FY2020 | −30.5% | (49.30) |
| FY2019 | 18.9% | (10.90) |
| FY2018 | 29.8% | 6.69 |
| FY2017 | 23.1% | (12.10) |
| FY2016 | 35.2% | 6.66 |
Against its own ten years
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| LQDA Liquidia Corporation compare | 33.4% |
| LNTH Lantheus Holdings, Inc. compare | 26.2% |
| KNSA Kiniksa Pharmaceuticals International, plc compare | 20.9% |
| ALKS Alkermes plc compare | 13.0% |
| HIMS Hims & Hers Health, Inc. compare | 3.22% |
| RDY Dr. Reddy's Laboratories Ltd compare | 2.88% |
| SUPN Indivior Pharmaceuticals Inc. | 2.26% |
| AMLX Amylyx Pharmaceuticals, Inc. compare | 0.00% |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | −1.89% |
| Drug Manufacturers Specialty & Generic industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue
More on SUPN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement